Novel Fibroblast Activation Protein Inhibitor-Based Targeted Theranostics for Radioiodine-Refractory Differentiated Thyroid Cancer Patients: A Pilot Study-Reference-Cited by-同舟云学术

Novel Fibroblast Activation Protein Inhibitor-Based Targeted Theranostics for Radioiodine-Refractory Differentiated Thyroid Cancer Patients: A Pilot Study

Published:2021-12-31 Issue: Volume: Page:
ISSN:1050-7256
Container-title:Thyroid
language:en
Short-container-title:Thyroid

Author:

Ballal Sanjana¹,Yadav Madhav Prasad¹,Moon Euy Sung²,Roesch Frank²,Kumari Samta¹,Agarwal Shipra³,Tripathi Madhavi¹,Sahoo Ranjit Kumar⁴,Mangu Bharadwaj Srinivas¹,Tupalli Avinash¹,Bal Chandrasekhar¹

Affiliation:

1. Department of Nuclear Medicine, All India Institute of Medical Sciences, New Delhi, India.

2. Department of Chemistry - TRIGA, Johannes Gutenberg University, Mainz, Germany.

3. Department of Pathology, All India Institute of Medical Sciences, New Delhi, India.

4. Department of Medical Oncology, All India Institute of Medical Sciences, New Delhi, India.

Publisher

Mary Ann Liebert Inc

Subject

Endocrinology,Endocrinology, Diabetes and Metabolism

Link

https://www.liebertpub.com/doi/pdf/10.1089/thy.2021.0412

Reference32 articles.

1. Increasing the effectiveness of radioactive iodine therapy in the treatment of thyroid cancer using Trichostatin A, a histone deacetylase inhibitor

2. Treatment strategies for radioactive iodine-refractory differentiated thyroid cancer

3. Progress in molecular-based management of differentiated thyroid cancer

4. The Impact of Distant Metastases at Presentation on Prognosis in Patients with Differentiated Carcinoma of the Thyroid Gland

5. Long-Term Outcome of 444 Patients with Distant Metastases from Papillary and Follicular Thyroid Carcinoma: Benefits and Limits of Radioiodine Therapy

Cited by 61 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Molecular Evolution of Multivalent OncoFAP Derivatives with Enhanced Tumor Uptake and Prolonged Tumor Retention;Journal of Medicinal Chemistry;2024-07-30

2. First Experience of Radionuclide Therapy With 177Lu-FAPI-2286 in a Patient With Metastatic Mediastinal Sarcoma;Clinical Nuclear Medicine;2024-07

3. Radiomolecular Theranostics With Fibroblast-Activation-Protein Inhibitors and Peptides;Seminars in Nuclear Medicine;2024-07

4. Tailoring Fibroblast-Activation Protein Targeting for Theranostics: A Comparative Preclinical Evaluation of the 68Ga- and 177Lu-Labeled Monomeric and Dimeric Fibroblast-Activation Protein Inhibitors DOTA.SA.FAPi and DOTAGA.(SA.FAPi)2;Molecules;2024-06-28

5. 68Ga-DOTA.SA.FAPi as a Versatile Diagnostic Probe for Various Epithelial Malignancies: A Head-to-Head Comparison with 18F-FDG;Academic Radiology;2024-06